Description
Microfluidic technologies offer unique control over the synthesis of polymeric particles enabling precise encapsulation strategies for labile therapeutic agents. In this work, we report a microfluidic approach for the generation of micronsize templated polymeric particles designed for the encapsulation of labile anticancer drugs targeting triple-negative breast cancer (TNBC). Using flow-focusing microfluidic devices, highly monodisperse double emulsions are produced with independent control over inner core size, shell thickness, and overall particle diameter. The mild hydrodynamic conditions and short residence times inherent to the microfluidic process preserve the chemical integrity and bioactivity of labile therapeutic compounds. The resulting particles exhibit narrow size distributions (CV < 5%), high encapsulation efficiency, and controlled release profiles, highlighting their potential to overcome stability and delivery challenges associated with conventional formulation techniques. This platform provides a versatile and reproducible strategy for the development of advanced drug delivery systems aimed at improving therapeutic efficacy and reducing systemic toxicity in the treatment of triple-negative breast cancer.